Ethic Inc. Has $844,000 Stock Position in Humana Inc. $HUM

Ethic Inc. cut its position in Humana Inc. (NYSE:HUM) by 5.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,491 shares of the insurance provider’s stock after selling 201 shares during the quarter. Ethic Inc.’s holdings in Humana were worth $844,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Humana by 16.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock worth $300,728,000 after acquiring an additional 158,528 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Humana by 104.2% in the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after purchasing an additional 3,281 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock valued at $33,256,000 after purchasing an additional 2,950 shares during the period. Circle Wealth Management LLC bought a new stake in Humana during the 1st quarter valued at $425,000. Finally, Arizona State Retirement System raised its holdings in Humana by 3.4% during the first quarter. Arizona State Retirement System now owns 35,337 shares of the insurance provider’s stock worth $9,350,000 after buying an additional 1,165 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of Humana stock opened at $292.81 on Tuesday. The firm has a market capitalization of $35.22 billion, a PE ratio of 22.47, a price-to-earnings-growth ratio of 1.70 and a beta of 0.42. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $315.35. The business’s 50-day moving average price is $281.75 and its 200-day moving average price is $258.84.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is 27.17%.

Analyst Ratings Changes

Several equities analysts recently weighed in on HUM shares. Robert W. Baird dropped their price target on shares of Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research report on Friday, July 25th. Bank of America raised their price objective on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Wolfe Research raised their target price on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research note on Monday, October 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $297.58.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.